This is a multi-center, randomized, open-label, parallel group trial to compare the efficacy of 9 ug interferon alfacon-1 administered sub-q three times per week for 72 weeks or 1 X day for 48 weeks to the same dose administered TiW for 48 wks in subjects with chronic HCV infection, previously untreated with interferon. Efficacy is defined by undetectable serum HCV RNa levels 24 wks following cessation of therapy.
Showing the most recent 10 out of 871 publications